1. Home
  2. CHMI vs TLSA Comparison

CHMI vs TLSA Comparison

Compare CHMI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

N/A

Current Price

$2.61

Market Cap

108.3M

Sector

Real Estate

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$1.15

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHMI
TLSA
Founded
2012
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.3M
145.1M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
CHMI
TLSA
Price
$2.61
$1.15
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$3.10
★ $7.97
AVG Volume (30 Days)
204.1K
★ 545.0K
Earning Date
11-05-2026
05-01-2026
Dividend Yield
★ 15.33%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$0.76
52 Week High
$2.98
$2.33

Technical Indicators

Market Signals
Indicator
CHMI
TLSA
Relative Strength Index (RSI) 28.47 59.09
Support Level $2.53 $0.90
Resistance Level $2.74 $1.20
Average True Range (ATR) 0.06 0.09
MACD -0.04 0.02
Stochastic Oscillator 0.00 94.69

Price Performance

Historical Comparison
CHMI
TLSA

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: